Tradestie Institutional Equity Comparison Engine
CING vs AZN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AZN Overall Edge
AZN Captures Institutional Edge (4โ0 Pillars ยท 9โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AstraZeneca PLC (AZN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AZN at 16.3x Forward P/E and 25.8% operating margin (+6.7% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against AZN sits in UNCLASSIFIED (8th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
AZN
CING N/M vs AZN 16.3x Fwd P/E
Growth & Margin Winner
AZN
Op Margin 0.0% vs 25.8% ยท YoY +0.0% vs +6.7%
Momentum & Technical Winner
AZN
1Y +36.4% vs +2.5% ยท 52W Pos 18% vs 49%
Options & Structure Winner
AZN
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (8th %ile IV)
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap
$62.5M
1M Return
+9.17%
1Y Return
+36.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
AZN
NASDAQ
AstraZeneca PLC
Pharmaceutical Preparations
$182.62
-0.76% 1D
Market Cap
$286.1B
1M Return
+11.38%
1Y Return
+2.48%
Forward P/E
16.3x
Unified AI Score
44.8 / 100
HOLD
Tech 32.0
Fund 38.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CING +36.39%
AZN +2.48%
Spread: +33.91 pp (CING Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CING TTM Op. Margin: 0.0%
AZN TTM Op. Margin: 25.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs AZN. Trailing 12-month operating profitability (CING 0.0% vs AZN 25.8%) and valuation multiples (CING N/M vs AZN 16.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CING | AZN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $62.5M | $286.1B | Larger Scale | AZN |
| Trailing P/E Ratio Valuation | N/M | 26.1x | Lower Multiple | AZN |
| Forward P/E Ratio Valuation | N/M | 16.3x | Lower Multiple | AZN |
| Revenue Growth (YoY) Growth | +0.0% | +6.7% | Higher Growth | AZN |
| Operating Margin (TTM) Profitability | 0.0% | 25.8% | Higher Margin | AZN |
| Net Profit Margin Profitability | 0.0% | 17.7% | Higher Margin | AZN |
| Return on Equity (ROE) Capital Efficiency | -198.7% | 22.6% | Higher ROE | AZN |
| 52-Week Range Position Momentum | 18% ($3โ$12) | 49% ($153โ$213) | Stronger Trend | AZN |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 117% Vol | 0.04ฮฒ ยท 32% Vol | Lower Realized Risk | AZN |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 44.8 / 100 (HOLD) | Higher Composite | Tie |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CING vs AZN Buy Guide
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
AZN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CING nor AZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.